{"id":"comparator-etoricoxib","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the production of pro-inflammatory prostaglandins while sparing the protective effects of COX-1-derived prostaglandins in the gastrointestinal tract and kidneys. This selective mechanism provides anti-inflammatory and analgesic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.","oneSentence":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:43:27.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"},{"name":"Acute pain"},{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT00092729","phase":"PHASE3","title":"An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-07","conditions":"Dysmenorrhea","enrollment":129},{"nctId":"NCT00140972","phase":"PHASE4","title":"A Study to Assess Etoricoxib Versus Diclofenac in Chinese Patients With Osteoarthritis of the Knee or Hip (0663-080)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-12-03","conditions":"Osteoarthritis","enrollment":160},{"nctId":"NCT00092703","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-06-27","conditions":"Osteoarthritis","enrollment":6000},{"nctId":"NCT00269191","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of an Investigational Drug in Patients With Osteoarthritis (0663-071)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02-05","conditions":"Osteoarthritis","enrollment":528},{"nctId":"NCT00142558","phase":"PHASE4","title":"A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-01-01","conditions":"Acute Gout","enrollment":180},{"nctId":"NCT00092768","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-076)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT00542087","phase":"PHASE3","title":"Etoricoxib vs. Diclofenac in OA (0663-805)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-03-22","conditions":"Osteoarthritis","enrollment":516},{"nctId":"NCT00092755","phase":"PHASE3","title":"An Investigational Drug in Patients With Osteoarthritis (0663-073)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-04-09","conditions":"Osteoarthritis","enrollment":548},{"nctId":"NCT00092781","phase":"PHASE3","title":"A Study of MK0663 and an Approved Drug in the Treatment of Osteoarthritis (0663-077)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-03-01","conditions":"Osteoarthritis","enrollment":500},{"nctId":"NCT01208207","phase":"PHASE3","title":"A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2010-09-27","conditions":"Spondylitis, Ankylosing","enrollment":1015},{"nctId":"NCT05683574","phase":"PHASE3","title":"Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-05-30","conditions":"Third Molar Extraction","enrollment":""},{"nctId":"NCT00393354","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-041)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":325},{"nctId":"NCT00242489","phase":"PHASE2","title":"Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"1998-06","conditions":"Osteoarthritis","enrollment":1167},{"nctId":"NCT00250445","phase":"PHASE3","title":"A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-01","conditions":"Rheumatoid Arthritis,Osteoarthritis","enrollment":23498},{"nctId":"NCT00393211","phase":"PHASE3","title":"Effect of Etoricoxib to Treat Chronic Low Back Pain (0663-042)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04","conditions":"Recurrent Low Back Pain","enrollment":319},{"nctId":"NCT00092742","phase":"PHASE3","title":"Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-02","conditions":"Rheumatoid Arthritis","enrollment":4086},{"nctId":"NCT00090181","phase":"PHASE4","title":"Study of MK0663 in Patients With Chronic Low Back Pain (0663-806)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-06","conditions":"Chronic Low Back Pain","enrollment":401},{"nctId":"NCT01462370","phase":"PHASE3","title":"Study to Assess the Safety and Efficacy of Etoricoxib Versus Ibuprofen in the Treatment of Dysmenorrhea (MK-0663-145 AM1)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2011-11","conditions":"Dysmenorrhea","enrollment":139},{"nctId":"NCT00788710","phase":"PHASE3","title":"A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-10","conditions":"Acute Pain Following a Total Abdominal Hysterectomy","enrollment":430},{"nctId":"NCT00945035","phase":"PHASE1","title":"Study of the Bioequivalence of the 20% and 30% Etoricoxib Tablet Formulations (0663-070)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11","conditions":"Pain","enrollment":36},{"nctId":"NCT00694369","phase":"PHASE3","title":"A Study to Asses the Effect of MK0663 in the Treatment of Patients With Postoperative Dental Pain (0663-092)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-06","conditions":"Postoperative Dental Pain","enrollment":588},{"nctId":"NCT00820027","phase":"PHASE3","title":"Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2008-12-15","conditions":"Pain, Postoperative","enrollment":776},{"nctId":"NCT01554163","phase":"PHASE3","title":"Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2012-03","conditions":"Osteoarthritis of the Knee","enrollment":239},{"nctId":"NCT00264147","phase":"PHASE2","title":"Rheumatoid Arthritis Dose Ranging Study (0663-086)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-01","conditions":"Rheumatoid Arthritis","enrollment":761},{"nctId":"NCT03422575","phase":"NA","title":"Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets","status":"COMPLETED","sponsor":"Dexa Medica Group","startDate":"2015-12","conditions":"Healthy","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":412,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Comparator: etoricoxib","genericName":"Comparator: etoricoxib","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}